康乃德生物 CNTB 深 沪
等待开盘 10-02 09:30:00 美东时间
0.9873
-0.113
-10.25%
华盛通- 最 高1.12
- 今 开1.11
- 成交量 582.83万股
- 最 低 0.9812
- 昨 收 1.10
- 总市值 6217.45万
- 52周最高 3.82
- 市盈率 静 --
- 换手率 9.25%
- 52周最低 0.98
- 委 比 92.31%
- 总股本 6297.43万
- 历史最高 29.274
- 量 比 0.39
- 振 幅 12.62%
- 历史最低 0.51
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $10 to $5.
10-01 00:54
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5
Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.
09-23 00:38
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart. The clinical-stage biopharmaceutical company is testing the anti-interleukin-4-receptor alpha antibody as an add-on treatment f...
09-15 23:46
Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate at 28 Days by 66% and Improved Lung Function Vs. Placebo
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced topline results from its global phase 2 study evaluating rademikibart, the...
09-15 19:09
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
Connect Biopharma announced positive topline results from its Phase 2 Seabreeze STAT asthma trial evaluating rademikibart, an anti-IL-4Rα antibody, as an add-on treatment for acute exacerbations in asthma patients with type 2 inflammation. Key findings include a 66% reduction in treatment failure rate at 28 days (though not statistically significant), a statistically significant improvement in lung function (FEV1) at Day 7, and a favorable safety...
09-15 11:00
